A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
for Breast Cancer
14 locations incl. Orlando
Sponsor: Terremoto Biosciences Inc.
Sex: All·Age: 18+
Code: NCT07109726·Phase 1, Phase 2·Recruiting·Listed Aug 2025